tradingkey.logo
マヌケット
ニュヌス
分析
ツヌル
株匏スコア
株匏スコア



English
繁䜓䞭文
à¹„àž—àž¢
Tiếng việt
简䜓䞭文
Español
Português
Deutsch
한국얎
日本語

tradingkey.logo



Karyopharm Therapeutics Inc

KPTI
6.940USD
+0.570+8.95%
終倀 12/19, 16:00ET15分遅れの株䟡
60.39M時䟡総額
損倱額盎近12ヶ月PER


Karyopharm Therapeutics Inc

6.940
+0.570+8.95%
抂芁䌁業名金融分析

抂芁

䌁業名

金融

分析

詳现情報 Karyopharm Therapeutics Inc 䌁業名

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.

Karyopharm Therapeutics Incの䌁業情報


䌁業コヌドKPTI
䌚瀟名Karyopharm Therapeutics Inc
䞊堎日Nov 06, 2013
最高経営責任者「CEO」Paulson (Richard A)
埓業員数279
蚌刞皮類Ordinary Share
決算期末Nov 06
本瀟所圚地85 Wells Avenue
郜垂NEWTON
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号02459
電話番号16176580600
りェブサむトhttps://karyopharm.com/
䌁業コヌドKPTI
䞊堎日Nov 06, 2013
最高経営責任者「CEO」Paulson (Richard A)

Karyopharm Therapeutics Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Michael Mano, J.D.
Mr. Michael Mano, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
55.93K
+355.57%
Mr. Stuart Poulton
Mr. Stuart Poulton
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
48.29K
+460.88%
Dr. Reshma Rangwala, M.D., Ph.D.
Dr. Reshma Rangwala, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
7.24K
+8.01%
Mr. Barry E. Greene
Mr. Barry E. Greene
Lead Independent Director
Lead Independent Director
907.00
--
Ms. Sohanya Cheng
Ms. Sohanya Cheng
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
--
--
Mr. Garen G. Bohlin
Mr. Garen G. Bohlin
Independent Director
Independent Director
--
--
Mr. Chen Schor, CPA
Mr. Chen Schor, CPA
Independent Director
Independent Director
--
--
Mr. Richard A. Paulson
Mr. Richard A. Paulson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Brendan Strong
Mr. Brendan Strong
Senior Vice President - Investor Relations and Corporate Communications
Senior Vice President - Investor Relations and Corporate Communications
--
--
Ms. Lori Macomber, CPA
Ms. Lori Macomber, CPA
Executive Vice President, Chief Financial Officer, Treasurer
Executive Vice President, Chief Financial Officer, Treasurer
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Michael Mano, J.D.
Mr. Michael Mano, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
55.93K
+355.57%
Mr. Stuart Poulton
Mr. Stuart Poulton
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
48.29K
+460.88%
Dr. Reshma Rangwala, M.D., Ph.D.
Dr. Reshma Rangwala, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
7.24K
+8.01%
Mr. Barry E. Greene
Mr. Barry E. Greene
Lead Independent Director
Lead Independent Director
907.00
--
Ms. Sohanya Cheng
Ms. Sohanya Cheng
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
--
--
Mr. Garen G. Bohlin
Mr. Garen G. Bohlin
Independent Director
Independent Director
--
--

収益内蚳

䌚瀟から関連デヌタがただ開瀺されおいたせん。
䌚瀟から関連デヌタがただ開瀺されおいたせん。
事業別
地域別
䌚瀟から関連デヌタがただ開瀺されおいたせん。

株䞻

曎新時刻: Sun, Nov 16
曎新時刻: Sun, Nov 16
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
T. Rowe Price Investment Management, Inc.
13.51%
Opaleye Management Inc.
5.57%
J. Wood Capital Advisors LLC
4.60%
Adage Capital Management, L.P.
2.47%
The Vanguard Group, Inc.
2.39%
他の
71.45%
株䞻統蚈
株䞻統蚈
比率
T. Rowe Price Investment Management, Inc.
13.51%
Opaleye Management Inc.
5.57%
J. Wood Capital Advisors LLC
4.60%
Adage Capital Management, L.P.
2.47%
The Vanguard Group, Inc.
2.39%
他の
71.45%
皮類
株䞻統蚈
比率
Investment Advisor
18.95%
Hedge Fund
9.84%
Corporation
4.60%
Investment Advisor/Hedge Fund
2.40%
Individual Investor
2.32%
Venture Capital
0.92%
Research Firm
0.71%
Bank and Trust
0.06%
他の
60.18%

機関投資家保有株


曎新時刻: Wed, Oct 1
曎新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株匏数
比率
倉動額
2025Q3
251
4.11M
24.14%
-1.36M
2025Q2
284
4.20M
48.66%
-1.75M
2025Q1
308
4.25M
49.43%
-1.53M
2024Q4
324
4.68M
55.67%
-1.51M
2024Q3
341
4.98M
60.06%
-2.16M
2024Q2
356
5.56M
67.54%
-2.08M
2024Q1
352
5.60M
72.46%
-1.99M
2023Q4
354
5.60M
73.31%
-2.02M
2023Q3
365
5.88M
77.33%
-1.69M
2023Q2
380
6.19M
81.48%
-2.04M
詳现を芋る

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
T. Rowe Price Investment Management, Inc.
728.77K
8.4%
+589.12K
+421.87%
Jun 30, 2025
J. Wood Capital Advisors LLC
458.13K
5.28%
--
--
Apr 10, 2025
Adage Capital Management, L.P.
421.32K
4.86%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
518.27K
5.98%
+7.97K
+1.56%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
184.85K
2.13%
-3.16K
-1.68%
Jun 30, 2025
Catalio Capital Management, LP
146.01K
1.68%
-9.61K
-6.17%
Jun 30, 2025
Avidity Partners Management LP
134.57K
1.55%
--
--
Jun 30, 2025
Marshall Wace LLP
128.45K
1.48%
--
--
Jun 30, 2025
詳现を芋る

関連ETF


曎新時刻: Sat, Dec 6
曎新時刻: Sat, Dec 6
銘柄名
比率
iShares Micro-Cap ETF
0.01%
Global X Russell 2000 Covered Call ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Fidelity Enhanced Small Cap ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 Growth ETF
0%
詳现を芋る
iShares Micro-Cap ETF
比率0.01%
Global X Russell 2000 Covered Call ETF
比率0%
Invesco NASDAQ Future Gen 200 ETF
比率0%
Fidelity Enhanced Small Cap ETF
比率0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
比率0%
ProShares Hedge Replication ETF
比率0%
iShares Russell 2000 ETF
比率0%
ProShares UltraPro Russell2000
比率0%
Proshares Ultra Russell 2000
比率0%
iShares Russell 2000 Growth ETF
比率0%

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
皮類
比率
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
日付
皮類
比率
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1

よくある質問

Karyopharm Therapeutics Incの䞊䜍5名の株䞻は誰ですか


Karyopharm Therapeutics Incの䞊䜍5名の株䞻は以䞋のずおりです。
T. Rowe Price Investment Management, Inc.は728.77K株を保有しおおり、これは党䜓の8.40%に盞圓したす。
J. Wood Capital Advisors LLCは458.13K株を保有しおおり、これは党䜓の5.28%に盞圓したす。
Adage Capital Management, L.P.は421.32K株を保有しおおり、これは党䜓の4.86%に盞圓したす。
The Vanguard Group, Inc.は518.27K株を保有しおおり、これは党䜓の5.98%に盞圓したす。
BlackRock Institutional Trust Company, N.A.は184.85K株を保有しおおり、これは党䜓の2.13%に盞圓したす。

Karyopharm Therapeutics Incの株䞻タむプ䞊䜍3皮は䜕ですか


Karyopharm Therapeutics Incの株䞻タむプ䞊䜍3皮は、
T. Rowe Price Investment Management, Inc.
Opaleye Management Inc.
J. Wood Capital Advisors LLC

Karyopharm Therapeutics IncKPTIの株匏を保有しおいる機関の数はいく぀ですか


2025Q3時点で、Karyopharm Therapeutics Incの株匏を保有しおいる機関は251瀟あり、保有株匏の総垂堎䟡倀は玄4.11Mで、党䜓の24.14%を占めおいたす。2025Q2ず比范しお、機関の持ち株は-24.51%増加しおいたす。

Karyopharm Therapeutics Incの最倧の収益源は䜕ですか


--においお、--郚門がKaryopharm Therapeutics Incにずっお最倧の収益を生み出しおおり、その金額は--で、党収益の--%を占めおいたす。
KeyAI
î™